Filing status
- Accounts due
- 30 September 2027
- Last accounts
- 31 December 2025
- Conf. stmt due
- 11 June 2027
- Last conf. stmt
- 28 May 2026
Medicines Evaluation Unit Limited
- Incorporated
- 28 May 1999 (27 years)
- Industry
- Other research and experimental development on natural sciences and engineering (72190)
- Owned by
- Accounts type
- Full
- Region
- South East
- Address
- 3 Forbury Place23 Forbury RoadReadingRG1 3JH
Charges
- Total
- 2
- Outstanding
- 0
- Part satisfied
- 0
- Satisfied
- 2
Officers 4 active
Officer details are public data from the Companies House register.
Director · Appointed 18 August 2026
British
Born May 1976 (50)
Corporate Secretary · Appointed 27 June 2025
Director · Appointed 13 June 2025
Also at Cro Solutions Limited, Iqvia Biotech Ltd.
British
Born October 1969 (57)
Director · Appointed 13 June 2025
British
Born July 1980 (46)
Officer history (19 former)
18 August 2026
18 August 2026
27 June 2025
13 June 2025
13 June 2025
13 June 2025
13 June 2025
13 June 2025
Resigned Batty, Elizabeth Pamela as Director
13 June 2025
13 June 2025
13 June 2025
13 June 2025
13 June 2025
13 June 2025
23 January 2024
23 January 2024
Appointed Batty, Elizabeth Pamela as Director
19 December 2018
1 September 2018
1 September 2018
16 November 2015
16 November 2015
14 February 2005
Resigned Langley, Stephen, Dr as Director
1 January 2005
20 December 2004
8 September 2003
8 September 2003
Appointed Langley, Stephen, Dr as Director
21 May 2001
21 May 2001
Resigned Fielding, Benjamin James as Secretary
30 March 2001
19 January 2001
Resigned Williams, Andrew James, Dr as Director
20 November 2000
20 November 2000
1 March 2000
Resigned Williams, Andrew James, Dr as Secretary
1 March 2000
Appointed Fielding, Benjamin James as Secretary
1 March 2000
28 May 1999
28 May 1999
28 May 1999
28 May 1999
Appointed Williams, Andrew James, Dr as Secretary
28 May 1999
28 May 1999
Appointed Williams, Andrew James, Dr as Director
28 May 1999
Ownership 1 active
People and entities with significant control, from the Companies House PSC register
Corporate entity · Notified 13 June 2025
Owns 75–100% of shares
Holds 75–100% of voting rights
Right to appoint and remove directors
Private Limited Company
Reg. no. 03022416
Former controllers (1)
13 June 2025
Ceased North West Lung Research Centre Charity — Owns 75–100% of shares
Group structure 20 shown
Ownership group derived from the Companies House PSC register
Iqvia RDS Holdings Owns 75–100% of shares
Iqvia Finance Ltd. Owns 75–100% of shares
Iqvia Ltd. Owns 75–100% of shares
Apira Limited Owns 75–100% of shares
Arc Bio Communications Limited Owns 75–100% of shares
Clintec International Ltd. Owns 75–100% of shares
Cro Solutions Limited Owns 75–100% of shares
Drugdev Limited Owns 75–100% of shares
Epg Communication Holdings Limited Owns 75–100% of shares
Gce Clin Solutions Limited Owns 75–100% of shares
Healthcare Business Information Limited Owns 75–100% of shares
Ims (UK) Pension Plan Trustee Company Limited Owns 75–100% of shares
Interface Clinical Services Ltd Owns 75–100% of shares
Iqvia Biotech Ltd. Owns 75–100% of shares
Iqvia Investment Holdings Limited Owns 75–100% of shares
Iqvia Solutions Finance UK V Ltd. Owns 75–100% of shares
Iqvia Solutions UK Limited Owns 75–100% of shares
Iqvia Technology Services Ltd. Owns 75–100% of shares
Medicines Evaluation Unit Limited This company Owns 75–100% of shares
Financials
Figures from 2025 accounts. Newer accounts, made up to 31 December 2025, are filed but not read yet. See them on Companies House
- Net Assets
- £38,296,895
- Cash
- £33,216,149
- Turnover
- £18,188,618
- Profit Before Tax
- £6,032,655
- Employees
- 160
- Debt Ratio
- 6%
- Current Ratio
- 14.6x
- Profit Margin
- 33%
- Return on Equity
- 14%
Trend
Turnover
Balance sheet detail
| 2025 | 2024 | 2023 | 2021 | 2020 | |
|---|---|---|---|---|---|
| Fixed Assets | £3,123,606 | £10,846,286 | £10,241,092 | £8,381,114 | £7,830,673 |
| Current Assets | £37,806,548 | £26,192,542 | £23,842,949 | £15,336,430 | £11,609,235 |
| Debtors | £4,590,399 | £6,688,361 | £7,215,446 | £3,457,173 | £3,932,565 |
| Cash | £33,216,149 | £19,504,181 | £16,627,503 | £11,879,257 | £7,676,670 |
| Creditors (< 1 year) | £2,585,038 | £2,353,957 | £3,786,641 | £1,567,723 | £921,331 |
| Net Current Assets | £35,221,510 | £23,838,585 | £20,056,308 | £13,768,707 | £10,687,904 |
| Net Assets | £38,296,895 | £34,636,650 | £30,226,961 | £22,086,762 | £18,455,518 |
| Shareholder Funds | £38,296,895 | £34,636,650 | £30,226,961 | £22,086,762 | £18,455,518 |
| Turnover | £18,188,618 | £18,166,529 | £17,573,750 | £14,709,377 | £11,588,792 |
| Cost of Sales | £7,977,897 | £7,509,622 | £8,086,711 | £7,736,977 | £5,867,512 |
| Gross Profit | £10,210,721 | £10,656,907 | £9,487,039 | £6,972,400 | £5,721,280 |
| Admin Expenses | £4,587,095 | £4,502,885 | £4,372,244 | £3,270,559 | £3,259,389 |
| Staff Costs | £7,890,005 | £7,070,329 | £6,731,693 | £5,071,564 | £5,247,826 |
| Operating Profit | £5,623,626 | £6,154,022 | £5,114,795 | £4,144,067 | £2,461,891 |
| Profit Before Tax | £6,032,655 | £7,086,083 | £4,976,762 | £4,802,186 | £2,050,063 |
| Tax | £692,934 | (£274,502) | (£168,890) | (£233,459) | (£204,839) |
| Profit for Period | £5,339,721 | £7,360,585 | £5,145,652 | £5,035,645 | £2,254,902 |
Filings 132
| Date | Description | Made Up To | Pages | |
|---|---|---|---|---|
| 30 September 2026 | Full accounts | 31 December 2025 | ||
| 8 September 2026 | Appointment of a director | |||
| 8 September 2026 | Termination of appointment of a director | |||
| 17 June 2026 | Director's details changed | |||
| 10 June 2026 | Confirmation statement with updates | 28 May 2026 |
Some other companies at this address
Other companies in this industry
Kettering
Reading
Peterborough
Horsham
Abingdon
Cambridge
By trade and location
Explore the largest companies
Need accounts figures, ownership or websites for thousands of companies? Bulk data & API →